3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
2
Gynecologic
2
Gastrointestinal
2
Breast
2
Sarcoma
1
Other hematologic neoplasm
1
Head & Neck
1
Genitourinary
1
Dermatologic
1
CNS
1
Conditions
Sarcoma
2
Urinary Bladder Neoplasms
1
Stomach Neoplasms
1
Prostatic Neoplasms
1
Pancreatic Neoplasms
1
Ovarian Neoplasms
1
Neuroblastoma
1
Neoplasms
1
Neoplasm Metastasis
1
Melanoma
1
Lung Neoplasms
1
Liver Neoplasms
1
Leukemia
1
Kidney Neoplasms
1
Glioblastoma
1
Esophageal Neoplasms
1
Disease
1
Colorectal Neoplasms
1
Carcinoma, Bronchogenic
1
Breast Neoplasms
1
Brain Neoplasms
1
Interventions
pembrolizumab
6
Magnetic Resonance Spectroscopy
6
Specimen Handling
5
Cyclophosphamide
5
Radiosurgery
3
Oncolytic Virotherapy
3
Nivolumab
3
Injections
3
Gemcitabine
3
Drug Therapy
3
Biopsy
3
fludarabine
2
belinostat
2
Riluzole
2
Paclitaxel
2
Ipilimumab
2
Filgrastim
2
Docetaxel
2
Cisplatin
2
Celecoxib
2
Carboplatin
2
Bortezomib
2
Blood Specimen Collection
2
Amifostine
2
AH 111585
2
tislelizumab
1
spartalizumab
1
seribantumab
1
selpercatinib
1
sargramostim
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Lung Neoplasms
×
Interleukin-15
×
Sarcoma
×
Clear all
NCT07410676
2026-02-18
EBNK-ST-001
Essen Biotech
Phase 1/2
Recruiting
83 enrolled